Novo Holdings says it is looking to fuel more early- and late-stage biotechs. The venture capital firm said that, over the next few years, it is plotting to “increase its investments in life science companies at all stages of development: from seed companies in the early phases to well-established, cash-generative companies,” with a focus on those in the U.S. and Europe.
Medical products maker ConvaTec Ltd plans to raise around $1.8 billion in an initial public offering (IPO) of new shares on the London Stock Exchange, it said on Monday, in a test of investor confidence after Britain's vote to leave the European Union.